MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • Laidlaw & Company Sees Actinium Pharmaceuticals, Inc. (ATNM) Going Higher 0 comments
    Jan 28, 2014 2:54 PM | about stocks: ATNM

    Actinium Pharmaceuticals is a public biopharmaceutical company specializing in the development of cancer drugs. The company's product candidates are based on its patented technology, co-developed with Memorial Sloan Kettering Cancer Center (MSKCC), for combining the cancer targeting precision of monoclonal antibodies (mAb) for targeting specific types of cells with the power of alpha emitting radioisotopes, the most potent cancer killing agents in existence.

    In November, Laidlaw & Company initiated coverage on ATNM, with a buy rating and a price target of $18.00. It is believed that ATNM's technology platform using the cancer-cell killing ability of alpha and beta-emitting isotopes will produce novel drugs that will ultimately become viable oncology treatments. Among its current projects:

    * Iomab-B, a combination of a monoclonal antibody and a beta-emitting radioisotope, is being developed for patients in need of a hematopoietic stem cell transplantation (HSCT) and is potentially entering Phase III in 2014, after showing impressive Phase I/II data.

    * Actimab-A is an innovative treatment for acute myeloid leukemia (AML), and is a radioimmunoconjugate consisting of a monoclonal antibody and the isotope actinium-225. Phase I data showed elimination of leukemia calls from blood in 67% of all evaluable patients who received a full dose. The Phase II portion of this trial to complete in mid-2014 and Actimab-A could possibly be launched by the end of 2019, potentially addressing a global AML market of $1 billion.

    * Broad Applications Possible for Several Cancer Types. Actinium has technology to attach radioisotopes to monoclonal antibodies. The company aims to use this platform to develop in-licensed monoclonal antibodies to target several cancer types and it has a strategy to improve on marketed oncology products by adding alpha-emitting isotopes.

    ATNM has an expert team of professionals, possessing the vision and desire to enhance shareholder value and position the company to benefit from increased market recognition of targeted payload therapies and an initial high-value, niche product model. For more information about the company and what it can offer investors, visit actiniumpharmaceuticals.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: ATNM
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.